| CONTACTS: |
César García,
Chairman and Chief Executive Officer |
|
818-709-1244
|
|
-or-
|
|
Ron Stabiner, The Wall Street Group, Inc. |
|
212-888-4848 |
CHATSWORTH, CA, June 26, 2008 - IRIS INTERNATIONAL, INC. (NASDAQ: IRIS),
a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, today announced that FORTUNE Small
Business (FSB) Magazine has named the Company to its list of the top 100 fastest growing companies in the United States. IRIS was ranked 80th, the first time the company has been
named to the FSB 100.
FSB also ranked IRIS 64th in revenue growth, 65th in total return to shareholders and 75th in earnings per share growth even after the Company's
significant investments in research and development in support of new product opportunities.
The annual FSB 100 list identifies the top-performing publicly traded companies in the U.S. based on consistent earnings and revenue growth and stock
performance over the past three years. FORTUNE Small Business compiled the list along with Chicago-based financial research firm Zacks Investment Research, which analyzed public
companies with annual revenues of less than $200 million and a stock price of more than $1.
"FORTUNE Small Business is one of the most prestigious business publications on the market, so we take it as a tremendous honor that they
recognize our company performance," said César García, Chairman, President and Chief Executive Officer. "Our FSB ranking is a reflection of the hard work our
management team and employees do on a daily basis and I thank each and every one of them for their continued dedication in providing excellent and innovative products and service
to our customers."
The FSB list of the top 100 fastest growing small companies in the US is published in the July/August 2008 issue of FORTUINE Small Business magazine.
The list is also available online by visiting: http://money.cnn.com/magazines/fsb/fsb100/2008/full_list/
ABOUT IRIS INTERNATIONAL, INC.
IRIS International a leading global in vitro diagnostics company focused on products that analyze particles and living cell forms and structures, or morphology of a variety of body
fluids. Our products leverage our strengths in flow imaging technology, particle recognition and automation to bring efficiency to hospital and commercial laboratories. The initial
applications for our technology have been in the urinalysis market and we are the leading worldwide provider of urine microscopy systems, with an installed based of over 1,800
systems in over 50 countries.
SAFE HARBOR PROVISION
This press release contains forward-looking statements made in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements include, but are not limited to, the Company's views on future financial performance, market growth, capital requirements, regulatory developments, new product
introductions and acquisitions, and are generally identified by phrases such as "thinks," "anticipates," "believes," "estimates,"
"expects," "intends," "plans," and similar words. Forward-looking statements are not guarantees of future performance and are inherently subject to
uncertainties and other factors which could cause actual results to differ materially from the forward-looking statement. These statements are based upon, among other things,
assumptions made by, and information currently available to, management, including management's own knowledge and assessment of the Company's industry, R&D initiatives,
competition and capital requirements. Other factors and uncertainties that could affect the Company's forward-looking statements include, among other things, the following:
identification of feasible new product initiatives, management of R&D efforts and the resulting successful development of new products and product platforms; obtaining
regulatory approvals for new and enhanced products; acceptance by customers of the Company's products; integration of acquired businesses; substantial expansion of
international sales; reliance on key suppliers; the potential need for changes in long-term strategy in response to future developments; future advances in diagnostic testing
methods and procedures; potential changes in government regulations and healthcare policies, both of which could adversely affect the economics of the diagnostic testing procedures
automated by the Company's products; rapid technological change in the microelectronics and software industries; and competitive factors, including pricing pressures and the
introduction by others of new products with similar or better functionality than our products. These and other risks are more fully described in the Company's filings with the
Securities and Exchange Commission, including the Company's most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q, which should be read in
conjunction herewith for a further discussion of important factors that could cause actual results to differ materially from those in the forward-looking statements. The Company
undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
